Canada - anglais - Health Canada

teva canada limited - raloxifene hydrochloride - tablet - 60mg - raloxifene hydrochloride 60mg - estrogen agonist-antagonists

Australie - anglais - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - raloxifene hydrochloride -

États-Unis - anglais - NLM (National Library of Medicine)

physicians total care, inc. - raloxifene hydrochloride (unii: 4f86w47br6) (raloxifene - unii:yx9162eo3i) - raloxifene hydrochloride 60 mg - evista is indicated for the treatment and prevention of osteoporosis in postmenopausal women [see clinical studies (14.1, 14.2)] . evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [see clinical studies (14.3)] . evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer [see clinical studies (14.4)] . the effect in the reduction in the incidence of breast cancer was shown in a study of postmenopausal women at high risk for breast cancer with a 5-year planned duration with a median follow-up of 4.3 years [see clinical studies (14.4)] . twenty-seven percent of the participants received drug for 5 years. the long-term effects and the recommended length of treatment are not known. high risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (lcis) or atypical hyperplasia, one or more first-degree relatives with breast cancer, or a 5-

États-Unis - anglais - NLM (National Library of Medicine)

eli lilly and company - raloxifene hydrochloride (unii: 4f86w47br6) (raloxifene - unii:yx9162eo3i) - raloxifene hydrochloride 60 mg - evista is indicated for the treatment and prevention of osteoporosis in postmenopausal women [see clinical studies (14.1, 14.2)] . evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [see clinical studies (14.3)] . evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer [see clinical studies (14.4)] . the effect in the reduction in the incidence of breast cancer was shown in a study of postmenopausal women at high risk for breast cancer with a 5-year planned duration with a median follow-up of 4.3 years [see clinical studies (14.4)] . twenty-seven percent of the participants received drug for 5 years. the long-term effects and the recommended length of treatment are not known. high risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (lcis) or atypical hyperplasia, one or more first-degree relatives with breast cancer, or a 5-y

Australie - anglais - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - raloxifene hydrochloride -

Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

mylan - raloxifene hydrochloride - tablet - 60mg

Japon - anglais - すりの適正使用協議会 RAD-AR Council, Japan

towa pharmaceutical co., ltd. - raloxifene hydrochloride - white oval tablet, major axis: approx.12.1mm, minor axis: approx. 6.6mm

Japon - anglais - すりの適正使用協議会 RAD-AR Council, Japan

sawai pharmaceutical co.,ltd. - raloxifene hydrochloride - white tablet, major axis: 12.2 mm, minor axis: 6.6 mm, thickness: 4.5 mm

Japon - anglais - すりの適正使用協議会 RAD-AR Council, Japan

nichi-iko pharmaceutical co.,ltd - raloxifene hydrochloride hydrate - white oval tablet, major axis: 12.2 mm, minor axis: 6.6 mm, thickness: 4.6 mm

Australie - anglais - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - raloxifene hydrochloride -